Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria

Journal of Infectious Diseases

Volumn 185, Issue 3, 2002, Pages 380-388

  Kublin, James G ^a,c   Dzinjalamala, Fraction K ^c,d   Kamwendo, Deborah D ^c,d,g   Malkin, Elissa M ^b,g,h   Cortese, Joseph F ^a   Martino, Lisa M ^a,g,i   Mukadam, Rabia A G ^c   Rogerson, Stephen J ^d,g,i,j   Lescano, Andres G ^b   Molyneux, Malcolm E ^d,e   Winstanley, Peter A ^e   Chimpeni, Phillips ^c,d   Taylor, Terrie E ^c,f   Plowe, Christopher V ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Malaria Project   (United States)

^d MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROGUANIL; DAPSONE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; MOLECULAR MARKER;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENETIC CODE; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALARIA; MUTATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ANTIMALARIALS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CHLOROGUANIDE; DAPSONE; DIHYDROPTEROATE SYNTHASE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT; MALARIA, FALCIPARUM; MUTATION; PROSPECTIVE STUDIES; PYRIMETHAMINE; SENSITIVITY AND SPECIFICITY; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT FAILURE;

EID: 0036467612     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/338566     Document Type: Article

References (47)

1. Beyond chloroquine: Implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa
2. Chlorproguanil-dapsone for treatment of drug resistant falciparum malaria in Tanzania
3. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: Selective pressure for resistance is a function of long elimination half-life
4. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites
5. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: Polymerase chain reaction methods for surveillance in Africa
6. Plasmodium falciparum: Rapid detection of dihydrofolate reductase mutations that confer resistance to cycloguanil and pyrimethamine
7. Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon
8. A mutation-specific PCR system to detect sequence variation in the dihydropteroate synthetase gene of Plasmodium falciparum
9. Use of a semi-nested PCR diagnosis test to evaluate antifolate resistance of Plasmodium falciparum isolates
10. Community pyrimethamine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: A model for deterring resistance
11. Direct evidence that asparagine at position 108 of the Plasmodium falciparum dihydrofolate reductase is involved in resistance to antifolate drugs in Tanzania
12. Plasmodium falciparum: Mutation pattern in the dihydrofolate reductase-thymidylate synthase genes of Vietnamese isolates, a novel mutation, and coexistence of two clones in a Thai patient
13. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthase and dihydrofolate reductase alleles in a large number of field samples of diverse origins
14. Pyrimethamine-resistant Plasmodium falciparum parasites among Tanzanian children: A facility-based study using the polymerase chain reaction
15. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance
16. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/pyrimethamine resistance
17. Molecular assays for surveillance of antifolate-resistant malaria
18. In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment
19. P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: Epidemiology and role in clinical resistance to antifolates
20. Development and comparison of quantitative assays for the dihydropteroate synthetase codon 540 mutation associated with sulfadoxine resistance in Plasmodium falciparum
21. Plasmodium falciparum: Detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion
22. Molecular epidemiology of malaria in Yaounde, Cameroon. II. Baseline frequency of point mutations in the dihydropteroate synthase gene of Plasmodium falciparum
23. Molecular epidemiology of malaria in Yaounde, Cameroon. V. Analysis of the omega repetitive region of the Plasmodium falciparum cg2 gene and chloroquine resistance
24. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali
25. Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Venezuela
26. Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis
27. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil
28. Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: A molecular epidemiologic study
29. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria
30. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum
31. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum
32. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria
33. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance
34. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutants expressed in yeast
35. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: Dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine
36. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization
37. On "The efficacy of antifolate antimalarial combinations in Africa"
38. More on "The efficacy of antifolate antimalarial combinations in Africa"
39. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy
40. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins
41. Antigenic diversity and the transmission dynamics of Plasmodium falciparum
42. Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children
43. A molecular marker for chloroquine-resistant falciparum malaria
44. Case-control studies of severe malaria
45. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria
46. Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: Parasitological resistance vs. therapeutic efficacy